NDAORALTABLET
Approved
Mar 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ZIAC (bisoprolol fumarate and hydrochlorothiazide) by Teva is clinical pharmacology bisoprolol fumarate and hctz have been used individually and in combination for the treatment of hypertension. Approved for the management of hypertension. First approved in 1993.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIAC is a fixed-dose combination of bisoprolol fumarate (a cardioselective beta-1 blocker) and hydrochlorothiazide (a thiazide diuretic) for the management of hypertension. The two agents work synergistically—bisoprolol provides beta-blockade while HCTZ enhances sodium and water excretion, with additive antihypertensive effects. The 6.25 mg HCTZ dose minimizes hypokalemia risk compared to higher diuretic doses.
$0.112MPart D
LOE ApproachingProduct is in late-stage LOE approaching phase with minimal Part D spending and claims, signaling a mature, contracted brand team focused on generics transition management.
Mechanism of Action
CLINICAL PHARMACOLOGY Bisoprolol fumarate and HCTZ have been used individually and in combination for the treatment of hypertension. The antihypertensive effects of these agents are additive; HCTZ 6.25 mg significantly increases the antihypertensive effect of bisoprolol fumarate. The incidence of…
Worked on ZIAC at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.